FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043940516> ?p ?o ?g. }

• W2043940516 endingPage "621" @default.
• W2043940516 startingPage "621" @default.
• W2043940516 abstract "Predictors of treatment resistance and relapse have not been well described in antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitis.To identify clinical, pathologic, and serologic predictors of treatment resistance and relapse in a community-based cohort of patients with ANCA-associated vasculitis.Cohort of patients identified at or near the time of biopsy diagnosis and followed as clinically indicated.The Glomerular Disease Collaborative Network.350 patients who received a new diagnosis of ANCA-associated vasculitis between 1985 and 2003 and were followed for a median of 49 months.Patients were categorized according to whether they had antiproteinase-3 (anti-PR3) antibodies or antimyeloperoxidase (anti-MPO) antibodies. Organ involvement was determined by biopsy or by well-defined clinical criteria. Treatment resistance was defined as progressive decline in kidney function with active urine sediment or the persistence or appearance of extrarenal manifestations. Relapse was defined as the time to the resurgence of vasculitic symptoms.Treatment resistance affected 23% of 334 treated patients and was associated with female sex, black ethnicity, and presentation with severe kidney disease (odds ratio per serum creatinine elevation of 100 micromol/L [1.13 mg/dL], 1.28 [95% CI, 1.16 to 1.39]). The following factors were associated with relapse in 258 (77%) patients who attained remission: seropositivity for anti-PR3 antibodies (hazard ratio, 1.87 [CI, 1.11 to 3.14]) and disease of the lung (hazard ratio, 1.71 [CI, 1.04 to 2.81]) or upper respiratory tract (hazard ratio, 1.73 [CI, 1.04 to 2.88]). Relapses occurred in 26% of patients with no risk factors versus 73% of patients with all 3 risk factors (hazard ratio, 3.7 [CI, 1.4 to 9.7]). Among 143 patients attaining remission who subsequently stopped all immunosuppressant therapy, relapse rates were similar for those who had received cyclophosphamide therapy for 6 months or less (34%) compared with those treated for a longer duration (35%), even after adjusting for risk factors for relapse (hazard ratio, 1.41 [CI, 0.80 to 2.50]).The cohort mostly included patients with biopsy-proven kidney disease. Patients were not followed with uniform treatment protocols, and only limited information about their clinical course before diagnosis was available.Female or black patients, or those with severe kidney disease, may be resistant to initial treatment more often than other patients with ANCA-associated small-vessel vasculitis. Increased risk for relapse appears to be related to the presence of lung or upper airway disease and anti-PR3 antibody seropositivity." @default.
• W2043940516 created "2016-06-24" @default.
• W2043940516 creator A5003827669 @default.
• W2043940516 creator A5007882790 @default.
• W2043940516 creator A5016307833 @default.
• W2043940516 creator A5042064091 @default.
• W2043940516 creator A5045128468 @default.
• W2043940516 creator A5079958549 @default.
• W2043940516 creator A5086851939 @default.
• W2043940516 date "2005-11-01" @default.
• W2043940516 modified "2023-10-16" @default.
• W2043940516 title "Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody–Associated Small-Vessel Vasculitis" @default.
• W2043940516 cites W1965359675 @default.
• W2043940516 cites W1970456986 @default.
• W2043940516 cites W1973617793 @default.
• W2043940516 cites W1981535363 @default.
• W2043940516 cites W1982754000 @default.
• W2043940516 cites W1987789273 @default.
• W2043940516 cites W1989119273 @default.
• W2043940516 cites W2006899677 @default.
• W2043940516 cites W2012332648 @default.
• W2043940516 cites W2015359612 @default.
• W2043940516 cites W2015836326 @default.
• W2043940516 cites W2017094546 @default.
• W2043940516 cites W2022541722 @default.
• W2043940516 cites W2025060860 @default.
• W2043940516 cites W2041565487 @default.
• W2043940516 cites W2044732270 @default.
• W2043940516 cites W2052968750 @default.
• W2043940516 cites W2053452241 @default.
• W2043940516 cites W2054585002 @default.
• W2043940516 cites W2055864845 @default.
• W2043940516 cites W2055896786 @default.
• W2043940516 cites W2061293215 @default.
• W2043940516 cites W2063100698 @default.
• W2043940516 cites W2070854468 @default.
• W2043940516 cites W2073208829 @default.
• W2043940516 cites W2074126987 @default.
• W2043940516 cites W2097043422 @default.
• W2043940516 cites W2101093436 @default.
• W2043940516 cites W2102454572 @default.
• W2043940516 cites W2104155486 @default.
• W2043940516 cites W2123092609 @default.
• W2043940516 cites W2123760012 @default.
• W2043940516 cites W2134743399 @default.
• W2043940516 cites W2135080336 @default.
• W2043940516 cites W2140547944 @default.
• W2043940516 cites W2150612435 @default.
• W2043940516 cites W2152658389 @default.
• W2043940516 cites W2162725007 @default.
• W2043940516 cites W2169700984 @default.
• W2043940516 cites W2264075806 @default.
• W2043940516 cites W2298868338 @default.
• W2043940516 cites W2317173431 @default.
• W2043940516 cites W2394793436 @default.
• W2043940516 cites W2419083838 @default.
• W2043940516 cites W2419314581 @default.
• W2043940516 cites W2468482338 @default.
• W2043940516 cites W2473041787 @default.
• W2043940516 cites W2581458651 @default.
• W2043940516 cites W161448161 @default.
• W2043940516 cites W2416113114 @default.
• W2043940516 doi "https://doi.org/10.7326/0003-4819-143-9-200511010-00005" @default.
• W2043940516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16263884" @default.
• W2043940516 hasPublicationYear "2005" @default.
• W2043940516 type Work @default.
• W2043940516 sameAs 2043940516 @default.
• W2043940516 citedByCount "393" @default.
• W2043940516 countsByYear W20439405162012 @default.
• W2043940516 countsByYear W20439405162013 @default.
• W2043940516 countsByYear W20439405162014 @default.
• W2043940516 countsByYear W20439405162015 @default.
• W2043940516 countsByYear W20439405162016 @default.
• W2043940516 countsByYear W20439405162017 @default.
• W2043940516 countsByYear W20439405162018 @default.
• W2043940516 countsByYear W20439405162019 @default.
• W2043940516 countsByYear W20439405162020 @default.
• W2043940516 countsByYear W20439405162021 @default.
• W2043940516 countsByYear W20439405162022 @default.
• W2043940516 countsByYear W20439405162023 @default.
• W2043940516 crossrefType "journal-article" @default.
• W2043940516 hasAuthorship W2043940516A5003827669 @default.
• W2043940516 hasAuthorship W2043940516A5007882790 @default.
• W2043940516 hasAuthorship W2043940516A5016307833 @default.
• W2043940516 hasAuthorship W2043940516A5042064091 @default.
• W2043940516 hasAuthorship W2043940516A5045128468 @default.
• W2043940516 hasAuthorship W2043940516A5079958549 @default.
• W2043940516 hasAuthorship W2043940516A5086851939 @default.
• W2043940516 hasConcept C126322002 @default.
• W2043940516 hasConcept C156957248 @default.
• W2043940516 hasConcept C159641895 @default.
• W2043940516 hasConcept C207103383 @default.
• W2043940516 hasConcept C24040308 @default.
• W2043940516 hasConcept C2776015282 @default.
• W2043940516 hasConcept C2779134260 @default.
• W2043940516 hasConcept C2780306776 @default.
• W2043940516 hasConcept C44249647 @default.
• W2043940516 hasConcept C71924100 @default.

• next